Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Q3 2025 value amounting to $698136.0.

  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures rose 1563.1% to $698136.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $698136.0, marking a year-over-year increase of 1563.1%. This contributed to the annual value of $680031.0 for FY2024, which is 3041.4% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Gains from Sales and Divestitures of $698136.0 as of Q3 2025, which was up 1563.1% from $342204.0 recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures peaked at $698136.0 during Q3 2025, and registered a low of $54349.0 during Q1 2025.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's median Gains from Sales and Divestitures value was $271925.0 (recorded in 2023), while the average stood at $327797.9.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 10790.65% in 2023, then crashed by 5253.61% in 2024.
  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures (Quarter) stood at $250805.0 in 2022, then soared by 107.91% to $521440.0 in 2023, then skyrocketed by 30.41% to $680031.0 in 2024, then increased by 2.66% to $698136.0 in 2025.
  • Its Gains from Sales and Divestitures was $698136.0 in Q3 2025, compared to $342204.0 in Q2 2025 and $54349.0 in Q1 2025.